The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

As it gets harder to offer compounded GLP-1s, many telehealth companies are pivoting to hormone replacement therapy.

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

This story mentions weight, weight loss, and/or GLP-1 drugs. In the last few years, GLP-1s, prescription weight-loss ...

So, while GLP-1 compounders have technically been operating ... them inspected (and will also typically do their own regular testing to verify what they receive), compounders just need to get ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

Unlike many oral small-molecule GLP-1 therapies being developed—whose ... manufacturing studies necessary to support human clinical testing of BLX-7006. With these critical studies underway ...

GLP-1 agonists can also come with other unpleasant side effects, like nausea and constipation. Meanwhile, a nimal testing of BRP showed no sign of these side-effects, or muscle loss, perhaps because ...